[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615182":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":16,"locations":21,"responsibleParty":33,"collaborators":10,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":56,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Atlas University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Breast Cancer Cohort",null,[12],{"name":13,"affiliation":14,"role":15},"Emine Yildirim, MD","Atlas University Faculty of Medicine","PRINCIPAL_INVESTIGATOR",[17],{"name":13,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+905056234825","opdreyildirim@gmail.com",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":10,"country":26,"countryCode":10,"cosmosGeoPoint":27,"geoPoint":32,"contacts":10},"Istanbul Atlas University Faculty of Medicine","RECRUITING","Istanbul","Turkey (Türkiye)",{"type":28,"coordinates":29},"Point",[30,31],28.94966,41.01384,{"lat":31,"lon":30},{"type":15,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Emine YILDIRIM","associate professor, MD","100615182",false,"NCT07289282","Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer","The Relationship Between microRNAs in Breast Cancer Subtypes and Response to Neoadjuvant Chemotherapy and Pathological Response","miRNA-NAC","Inclusion Criteria:\n\n* Histologically confirmed breast cancer\n* Planned to receive neoadjuvant chemotherapy\n* Biologically female\n* Age ≥ 18 years\n* Ability to provide informed consent\n* Adequate organ function to receive standard NAC (based on routine clinical evaluation)\n\nExclusion Criteria:\n\n* Presence of metastatic disease at diagnosis\n* Prior systemic chemotherapy for breast cancer\n* Pregnancy or breastfeeding\n* Active infection or uncontrolled comorbid conditions interfering with study participation\n* Any condition preventing collection of blood samples","FEMALE","18 Years",{"count":46,"type":47},80,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.",[51,52,53,54,55],"Breast Cancer","Neoadjuvant Therapy","Pathological Response","Invasive Breast Carcinoma","MicroRNAs",[57,58,59,60,61],"microRNA","Circulating microRNAs","Neoadjuvant Chemotherapy","Pathological Complete Response","Predictive Biomarkers","2026-03-30",{"date":64,"type":65},"2026-03-31","ACTUAL",{"date":67,"type":65},"2025-12-15",{"date":69,"type":47},"2026-12",{"name":5,"class":6},1]